Solventum Co. (NYSE:SOLV) Shares Sold by Farther Finance Advisors LLC

Farther Finance Advisors LLC decreased its stake in shares of Solventum Co. (NYSE:SOLV) by 27.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 757 shares of the company’s stock after selling 289 shares during the quarter. Farther Finance Advisors LLC’s holdings in Solventum were worth $50,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of SOLV. Modus Advisors LLC acquired a new stake in shares of Solventum in the fourth quarter worth $25,000. Stonebridge Financial Group LLC acquired a new stake in shares of Solventum in the fourth quarter worth $26,000. Crews Bank & Trust acquired a new stake in shares of Solventum in the fourth quarter worth $32,000. True Wealth Design LLC increased its stake in shares of Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after acquiring an additional 471 shares during the period. Finally, Synergy Asset Management LLC acquired a new stake in shares of Solventum in the fourth quarter worth $35,000.

Solventum Stock Performance

SOLV opened at $74.00 on Monday. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The company has a market cap of $12.80 billion and a price-to-earnings ratio of 26.91. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The firm’s fifty day simple moving average is $75.17 and its two-hundred day simple moving average is $71.61.

Analysts Set New Price Targets

SOLV has been the topic of a number of research reports. Bank of America increased their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. Mizuho increased their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. Wells Fargo & Company increased their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Morgan Stanley increased their price target on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group increased their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.